BiBBInstruments AB: The subscription price for warrants of series TO 1 set at SEK 3.25 per share
BiBBInstruments AB (“BiBB” or the “Company”) issued a total of 2,755,282 warrants of series TO 1 (“the Warrants” or “TO1”) in connection with the Company’s rights issue of units that was...
BiBB Receives U.S. Patent Notice of Allowance for EndoDrill®
BiBBInstruments AB (“BiBB” or the “Company”), a cancer diagnostics company developing EndoDrill® – the world’s first market-cleared powered biopsy instrument for endoscopy – today announced it has received a Notice of...
BiBB and TaeWoong Medical USA Sign Letter of Intent for U.S. Commercialization of EndoDrill® GI
BiBBInstruments AB (“BiBB” or “the Company”), developer of EndoDrill® – the world’s first market-cleared powered biopsy instrument for endoscopy – today announced that it has signed a non-binding Letter of Intent...
BiBB Receives Notice of Allowance for Additional EndoDrill Patent in China
The cancer diagnostics company BiBB Instruments AB (“BiBB” or “the Company”), which develops EndoDrill® – the world’s first market-cleared powered biopsy instrument for endoscopy – announces that the Company has received...
Successful Live Broadcasted Patient Case with EndoDrill® GI in Porto, Portugal
The cancer diagnostics company BiBBInstruments AB (“BiBB” or “the Company”), which develops EndoDrill® – the world’s first CE-marked electric-driven biopsy instrument for endoscopy – announces that EndoDrill® GI has been successfully...
First liver cases with EndoDrill GI performed in the USA
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), the developer of EndoDrill® – the world’s first market-cleared powered biopsy instrument for endoscopy – announces that Dr. Mohammed Barawi, Medical...
BiBB participated in clinical cases with EndoDrill GI in Germany for the indication EUS-guided liver biopsy
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”), the developer of EndoDrill®, the world’s first market-cleared, powered biopsy instrument for endoscopy, announces that BiBB participated in clinical cases involving...
BiBB receives first order for EndoDrill GI from a university hospital in the US
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”), the developer of EndoDrill®, the world’s first market-cleared, electric-driven biopsy instrument for endoscopy, announces that the first order for EndoDrill® GI...
BiBBInstruments announces final outcome of rights issue
BiBBInstruments AB (“BiBB” or the “Company”) today announces the final outcome of the rights issue of units of approximately SEK 36.5 million that was announced by the Company on 8 November...
BiBBInstruments announces preliminary outcome of rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA,...
Clinical evaluation at Karolinska University Hospital is progressing
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”), the developer of EndoDrill®, the world’s first market-cleared, electric-driven biopsy instrument for endoscopy, announces that the Company’s clinical evaluation is proceeding...
Well-executed clinical introduction of EndoDrill® GI at Sahlgrenska University Hospital in Sweden
The cancer diagnostics company BiBBInstruments AB (“BiBB” and the “Company”), the developer of EndoDrill®, the world’s first market-cleared electric-driven biopsy instrument for endoscopy, announces that the first clinical tissue sampling procedures...